Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has ...

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

Marcus & Millichap’s IPA Capital Markets Arranges $75 Million Financing for Midtown Manhattan Office-to-Residential ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

In a report released today, Akash Tewari from Jefferies assigned a Buy rating to Pfizer (PFE – Research Report), with a price target of ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock (NYSE:ABBV). PFE stock trades at a much lower multiple of 11x ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with ...

This big drugmaker's current challenges present an excellent buying opportunity for forward-thinking investors.

Pharmaceutical giant Pfizer ( PFE 1.12%) and social media platform Snap ( SNAP 1.29%) belong to this group: Both have ...

But is the stock still worth buying in hopes of a recovery over the long term? To answer that question in more detail, let's put this setback into context.

Pfizer Inc. (NYSE: PFE) experienced a notable uptick in its stock price during Monday’s trading session, climbing by +2.12% to reach $29.89 at 11:10 AM EDT. This positive movement comes in the wake of ...

Vaxcyte Inc.’s stock soared 42% Tuesday, after the vaccine maker reported positive results from an early-stage trial of its ...